I. Introduction
Brief overview of schizophrenia spectrum and other psychosis disorders.
Importance of medication treatment in symptom management and improving patients’ quality of life.
II. Antipsychotic Medications
Definition: Antipsychotic medications are a class of drugs used to manage the symptoms of schizophrenia spectrum and other psychosis disorders by targeting neurotransmitter imbalances in the brain.
III. First-Generation Antipsychotics (FGAs)
Definition: FGAs, also known as typical antipsychotics, were the initial class of antipsychotic medications developed.
III.A Mechanism of Action
Blockade of dopamine D2 receptors, particularly in the mesolimbic pathway (Smith et al., 2020).
III.B Common First-Generation Antipsychotics
Haloperidol (Haldol) – High potency, often used in acute settings (Jones et al., 2019).
Chlorpromazine (Thorazine) – Lower potency, known for its sedative effects (Davis et al., 2021).
III.C Side Effects
Extrapyramidal symptoms (EPS) – Movement disorders like dystonia, parkinsonism (Miller & Johnson, 2018).
Tardive dyskinesia (TD) – Involuntary repetitive movements (Robinson et al., 2017).
IV. Second-Generation Antipsychotics (SGAs)
Definition: SGAs, also known as atypical antipsychotics, were developed to address limitations and side effects of FGAs.
IV.A Mechanism of Action
Serotonin-dopamine antagonism.
Targeting both positive and negative symptoms (Jones & Smith, 2022).
IV.B Common Second-Generation Antipsychotics
Risperidone (Risperdal) – Effective against positive and negative symptoms (Brown et al., 2020).
Aripiprazole (Abilify) – Partial dopamine agonist, minimal metabolic effects (Garcia et al., 2019).
IV.C Side Effects
Metabolic effects – Weight gain, diabetes risk (Martin et al., 2021).
QTc prolongation – Risk of arrhythmias (Lee et al., 2023).
V. Third-Generation Antipsychotics
Definition: Third-generation antipsychotics offer benefits of both FGAs and SGAs while minimizing side effects.
V.A Mechanism of Action
Serotonin-dopamine activity modulation.
Partial agonism and antagonism at dopamine receptors (Anderson & White, 2022).
V.B Common Third-Generation Antipsychotics
Brexpiprazole (Rexulti) – Positive and negative symptom improvement (Thomas et al., 2019).
Cariprazine (Vraylar) – Dopamine D3 receptor partial agonist (Hill et al., 2020).
V.C Side Effects
Akathisia – Restlessness and motor agitation (Parker et al., 2018).
Nausea and vomiting – Common upon initiation (Carter et al., 2019).
VI. Combination and Augmentation Strategies
Use of antipsychotics with mood stabilizers or antidepressants (Brown & Johnson, 2023).
VII. Monitoring and Adherence
Regular symptom and side effect monitoring.
Addressing challenges related to medication adherence (Roberts et al., 2023).
VIII. Conclusion
Recap the significance of psychotropic medications in managing schizophrenia spectrum and other psychosis disorders.
IX. References
Anderson J, White L. (2022). Mechanisms of Action of Third-Generation Antipsychotics. Journal of Psychopharmacology.
Brown A, Johnson B. (2023). Combination Strategies in Antipsychotic Treatment. Schizophrenia Bulletin.
Carter C, et al. (2019). Side Effects of Third-Generation Antipsychotics. Psychiatry Research.
Davis D, et al. (2021). Comparative Efficacy of First-Generation and Second-Generation Antipsychotics. JAMA Psychiatry.
Garcia E, et al. (2019). Metabolic Effects of Aripiprazole. Journal of Clinical Psychopharmacology.
